ASO Author Reflections: What are the Indications for Conversion Surgery for Initially Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel? Is Surgery Really Worthwhile after Sufficient Chemotherapy?

被引：1
|
作者：
Ushida, Yuta [1 ]
Inoue, Yosuke [1 ]
Oba, Atsushi [1 ]
Mie, Takafumi [1 ]
Ito, Hiromichi [1 ]
Ono, Yoshihiro [1 ]
Sato, Takafumi [1 ]
Ozaka, Masato [1 ]
Sasaki, Takashi [1 ]
Saiura, Akio [1 ,2 ]
Sasahira, Naoki [1 ]
Takahashi, Yu [1 ]
机构：
[1] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Gastroenterol Surg, Tokyo, Japan
[2] Juntendo Univ Hosp, Dept Hepatobiliary Pancreat Surg, Tokyo, Japan
来源：
ANNALS OF SURGICAL ONCOLOGY | 2022年 / 29卷 / 08期
关键词：
D O I：
10.1245/s10434-022-11621-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：5051 / 5052
页数：2
相关论文
共 48 条
  • [31] Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer Potentially Improves Survival and Facilitates Surgery
    Miyasaka, Yoshihiro
    Ohtsuka, Takao
    Kimura, Ryuichiro
    Matsuda, Ryota
    Mori, Yasuhisa
    Nakata, Kohei
    Kakihara, Daisuke
    Fujimori, Nao
    Ohno, Takamasa
    Oda, Yoshinao
    Nakamura, Masafumi
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (05) : 1528 - 1534
  • [32] Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer Potentially Improves Survival and Facilitates Surgery
    Yoshihiro Miyasaka
    Takao Ohtsuka
    Ryuichiro Kimura
    Ryota Matsuda
    Yasuhisa Mori
    Kohei Nakata
    Daisuke Kakihara
    Nao Fujimori
    Takamasa Ohno
    Yoshinao Oda
    Masafumi Nakamura
    Annals of Surgical Oncology, 2019, 26 : 1528 - 1534
  • [33] Clinical impact of multimodal treatment including chemoradiotherapy, conversion surgery and postoperative chemotherapy for borderline resectable and unresectable locally advanced pancreatic cancer without disease progression after gemcitabine plus nab-paclitaxel
    Umezawa, Rei
    Mizuma, Masamichi
    Nakagawa, Kei
    Yamamoto, Takaya
    Takahashi, Noriyoshi
    Suzuki, Yu
    Kishida, Keita
    Omata, So
    Unno, Michiaki
    Jingu, Keiichi
    PANCREATOLOGY, 2023, 23 (06) : 650 - 656
  • [34] Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel
    Tsuyoshi Shirakawa
    Akitaka Makiyama
    Mototsugu Shimokawa
    Taiga Otsuka
    Yudai Shinohara
    Futa Koga
    Yujiro Ueda
    Junichi Nakazawa
    Satoshi Otsu
    Azusa Komori
    Shiho Arima
    Masaru Fukahori
    Hiroki Taguchi
    Takuya Honda
    Taro Shibuki
    Kenta Nio
    Yasushi Ide
    Norio Ureshino
    Toshihiko Mizuta
    Kenji Mitsugi
    Koichi Akashi
    Eishi Baba
    Scientific Reports, 14
  • [35] Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer
    Chen, Jiayuan
    Hua, Qingling
    Wang, Haihong
    Zhang, Dejun
    Zhao, Lei
    Yu, Dandan
    Pi, Guoliang
    Zhang, Tao
    Lin, Zhenyu
    BMC CANCER, 2021, 21 (01)
  • [36] Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer
    Jiayuan Chen
    Qingling Hua
    Haihong Wang
    Dejun Zhang
    Lei Zhao
    Dandan Yu
    Guoliang Pi
    Tao Zhang
    Zhenyu Lin
    BMC Cancer, 21
  • [37] Downsizing Chemotherapy for Locally Advanced Pancreatic Cancer Treated With Nab-Paclitaxel Plus Gemcitabine Followed by Radical Surgery: Toxicity and Clinical Outcome
    Kagawa, S.
    Yoshitomi, H.
    Shimizu, H.
    Ohtsuka, M.
    Furukawa, K.
    Takayashiki, T.
    Takano, S.
    Kuboki, S.
    Suzuki, D.
    Sakai, N.
    Nojima, H.
    Miyazaki, M.
    PANCREAS, 2016, 45 (10) : 1513 - 1513
  • [38] Efficacy of S-1 compared to modified FOLFIRINOX as second-line chemotherapy regimens after gemcitabine plus nab-paclitaxel for patients with metastatic pancreatic cancer.
    Kimura, Gen
    Takahashi, Hideaki
    Umemoto, Kumiko
    Watanabe, Kazuo
    Sasaki, Mitsuhito
    Hashimoto, Yusuke
    Imaoka, Hiroshi
    Ohno, Izumi
    Mitsunaga, Shuichi
    Ikeda, Masafumi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [39] Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection
    Wolfe, Adam R.
    Prabhakar, Dhivya
    Yildiz, Vedat O.
    Cloyd, Jordan M.
    Dillhoff, Mary
    Abushahin, Laith
    Diaz, Dayssy Alexandra
    Miller, Eric D.
    Chen, Wei
    Frankel, Wendy L.
    Noonan, Anne
    Williams, Terence M.
    CANCER MEDICINE, 2020, 9 (13): : 4711 - 4723
  • [40] ASO Author Reflections: Which was the Better Regimen (Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1) as Neoadjuvant Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma (R/BR-PDAC)?
    Yamada, Daisaku
    Kobayashi, Shogo
    Takahashi, Hidenori
    Iwagami, Yoshifumi
    Akita, Hirofumi
    Asukai, Kei
    Shimizu, Junzo
    Yamada, Terumasa
    Tanemura, Masahiro
    Yokoyama, Shigekazu
    Tsujie, Masanori
    Asaoka, Tadafumi
    Takeda, Yutaka
    Morimoto, Osakuni
    Tomokuni, Akira
    Doki, Yuichiro
    Eguchi, Hidetoshi
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (07) : 4702 - 4703
12345